JosephBuscemaMD
Obstetrics & Gynecology • Tucson, AZGeneral Gynecology, Gynecologic Oncology
Assistant Professor of Obstetrics & Gynecology, Johns Hopkins University
Dr. Buscema is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
603 N Wilmot Rd
Ste 151
Tucson, AZ 85711Phone+1 520-886-0206Fax+1 520-886-0829
Education & Training
Johns Hopkins UniversityFellowship, Gynecologic Oncology, 1984 - 1986- Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 1980 - 1984
- Johns Hopkins University School of MedicineClass of 1980
Certifications & Licensure
AZ State Medical License 2002 - 2025
MD State Medical License 1980 - 2012- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Top Doctors:Arizona State Castle Connolly, 2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACS) American College of Surgeons
Clinical Trials
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
- A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Start of enrollment: 2018 Apr 10
Publications & Presentations
PubMed
- Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomiz...Matthew A Powell, David Cibula, David M O'Malley, Ingrid Boere, Mark S Shahin
Gynecologic Oncology. 2025-01-01 - A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák
Future Oncology. 2025-01-01 - Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Thierry André, Angela Jain
British Journal of Clinical Pharmacology. 2024-11-08
Press Mentions
Who’s Who in Arizona Healthcare for 2024December 15th, 2023
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
